Last update 02 May 2024
Bharat Biotech International Ltd.
Last update 02 May 2024
Overview
Basic Info
Introduction Bharat Biotech International Ltd. is a company that specializes in the research, development, manufacturing, marketing, and distribution of vaccines and biotherapeutics. Its primary focus is on creating innovative healthcare solutions targeting region-specific diseases often neglected. Among the firm's offerings are Revac-B+, REGEN-D, HNVAC, ROTAVAC and potential vaccines for diseases like chikungunya, chandipura, HPV, and Ebola. Established in 1996 by Krishna Murthy Ella and Suchitra K. Ella, Bharat Biotech International Ltd. is based in Hyderabad, India. |
Tags
Infectious Diseases
Respiratory Diseases
Nervous System Diseases
Prophylactic vaccine
Vaccine
Inactivated vaccine
Disease domain score
A glimpse into the focused therapeutic areas
No Data
Technology Platform
Most used technologies in drug development
No Data
Targets
Most frequently developed targets
No Data
| Disease Domain | Count |
|---|---|
| Infectious Diseases | 22 |
| Nervous System Diseases | 3 |
| Endocrinology and Metabolic Disease | 1 |
| Top 5 Drug Type | Count |
|---|---|
| Prophylactic vaccine | 15 |
| Vaccine | 5 |
| Toxoid vaccine | 3 |
| Inactivated vaccine | 3 |
| Live attenuated vaccine | 2 |
Related
29
Drugs associated with Bharat Biotech International Ltd.Target |
Mechanism SARS-CoV-2 S protein modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. IN |
First Approval Date06 Sep 2022 |
Target |
Mechanism SARS-CoV-2 antigen inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. IN |
First Approval Date03 Jan 2021 |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. IN |
First Approval Date19 Feb 2016 |
76
Clinical Trials associated with Bharat Biotech International Ltd.An Open-Labelled, Phase I Clinical Trial to Assess the Safety Reactogenicity, Tolerability and Immunogenicity of a Tuberculosis Vaccine BBV169 (MTBVAC), in Healthy Indian Adults. - MTBVAC
Start Date22 Jan 2024 |
Sponsor / Collaborator |
A Phase 2, Randomized, Double Blind, Multicenter Study to Evaluate the Immunogenicity,Reactogenicity and Safety of an Intranasal Adenoviral vector COVID-19 vaccine (BBV154) in Healthy Volunteers. - BBV154 INTRANASAL PHASE 2 STUDY
Start Date13 Sep 2023 |
Sponsor / Collaborator |
The Efficacy of Three Doses of Live Attenuated, Oral Rotavirus Vaccine 116E (ROTAVAC 5D) in Chilean Infants.
This is a randomized, double-blind, phase 3 study to evaluate the Efficacy,Safety, and Immunogenicity of ROTAVAC 5D, a live attenuated rotavirus vaccine in healthy infants aged 6-8 weeks.
A total of 5800 healthy Chilean infants will be recruited in this study and randomized to receive either vaccine or placebo in 1:1 ratio. Among these participants 300 will be categorized to immunogenicity cohort, 150 from each group, and blood samples will be collected to assess the immune response.
A total of 5800 healthy Chilean infants will be recruited in this study and randomized to receive either vaccine or placebo in 1:1 ratio. Among these participants 300 will be categorized to immunogenicity cohort, 150 from each group, and blood samples will be collected to assess the immune response.
Start Date07 Jul 2023 |
Sponsor / Collaborator |
100 Clinical Results associated with Bharat Biotech International Ltd.
Login to view more data
0 Patents (Medical) associated with Bharat Biotech International Ltd.
Login to view more data
19
Literatures (Medical) associated with Bharat Biotech International Ltd.2021·Indian Journal of Advances in Chemical Science
A rapid and reproducible near infrared spectroscopy based method for solvency power measurement of dearomatized solvents
Author: Pandey, Dharmendra ; Gupta, Shalini ; Newalkar, Bharat
Today, dearomatized hydrocarbon solvents are widely used in manufacturing, cosmetic, and fast moving consumer goods sectors due to onset of stringent environmental norms. Conventionally, the solvency of such solvents is measured in terms of Kauri Butanol (KB) value. The measurement of KB value, as per ASTM-D1133, is costly, time consuming, and tedious process. To overcome such limitations, the present study reports, an innovative method using Fourier Transform-Near Infra-Red (FT-NIR) spectroscopy based rapid and reliable technique for estimation of solvency power. Partial least squares regression was used to develop calibration and prediction of KB value by the use of TQ Analyst 8 software associated with FT-NIR analyzer. This method is fast, safe, reliable, nondestructive, and inexpensive contrary to conventional procedures. The results obtained based on developed method are found to be in good agreement with those reported based on standard test method, i.e., ASTM-D1133.
09 Nov 2020·RSC AdvancesQ3 · CHEMISTRY
Chromium-free Cu@Mg/γ-AlO - an active catalyst for selective hydrogenation of furfural to furfuryl alcohol
Q3 · CHEMISTRY
ArticleOA
Author: Arundhathi, Racha ; Reddy, Panyala Linga ; Samanta, Chanchal ; Newalkar, Bharat L.
Development of a chromium (Cr)-free hydrogenation catalyst is very important to replace the existing hazardous Cr based catalyst used in the furfural hydrogenation to furfuryl alcohol. Herein, we report synthesis of well-dispersed copper nanoparticles supported on hydrothermally stable magnesium doped alumina (Cu@Mg/γ-Al2O3) for selective hydrogenation of furfural to furfuryl alcohol. The prepared catalyst was characterized by X-ray Photoelectron Spectroscopy (XPS), Auger Electron Spectroscopy (AES), Powder X-ray Diffraction (PXRD), Surface Area Analysis (SAA), High Resolution-Transmission Electron Microscopy (HR-TEM), Temperature Programmed Reduction/Desorption (TPR/TPD) and Inductively Coupled Plasma-Atomic Emission Spectroscopy (ICP-AES) to understand textural properties of the catalyst. The prepared catalyst was found to be highly active and selective with 99% conversion of furfural and 94% selectivity for furfuryl alcohol under solvent free conditions at 443.15 K and 2 MPa of hydrogen pressure. It was also observed that the Cu@Mg/γ-Al2O3 catalyst is reusable (up to six runs) while maintaining its high activity and selectivity (≥94%) in the hydrogenation of furfural to furfuryl alcohol.
31 Aug 2020·Tribology International
Performance properties of lithium greases with PTFE particles as additive: Controlling parameter- size or shape?
Author: Kumar, Nikhil ; Saini, Vinay ; Bijwe, Jayashree
The tribo-performance of Lithium-based synthetic greases based on poly-alpha olefin as a base-stock and Polytetrafluoroethylene particles (4 wt%) of different sizes viz. 50 nm, 6 μm, 9 μm and 12 μm and shapes as a functional additive were developed and tribo-investigated. Tribo-results revealed that the smaller the size, better was the performance in general. However, there was a strong competition between small particles 6 μm and nano-particles (50 nm) for best performance. The 6 μm particles showed slightly better performance, mainly because of their spherical shape. It was concluded that both the size and shape of particles were the controlling factors.
84
News (Medical) associated with Bharat Biotech International Ltd.14 Mar 2024
DUBLIN--(
BUSINESS WIRE
)--The
"COVID-19 Monthly Snapshot"
newsletter has been added to
ResearchAndMarkets.com's
offering.
Newsletter includes:
Impact of the COVID-19 pandemic on the healthcare industry, along with major highlights
Comparative analysis (November 2023 vs. October 2023) pertaining to COVID19-related diagnostics, therapeutics, and vaccine developments
Pipeline analysis of therapies and assessment of the most promising drug candidates
Business strategies adopted by market players in the field of COVID-19 diagnostics in November 2023
Implications of faster clinical trials and approvals of Food and Drug Administration (FDA)
Key findings and impact analysis of COVID-19 on pharmaceutical business
Growth Opportunities in an Era of Change Advancements since October 2023
November 2023
There was one non-commercial partnership reported, while no commercial collaboration was reported in November 2023 among the COVID-19 diagnostics, therapeutics, and vaccines market.
In November 2023, the total number of treatment options was 226.
Key players evaluating Phase 3 vaccine and drug candidates included Biological E. Limited, SK Bioscience Co., Ltd., AstraZeneca/the University of Oxford, Novavax, Sinopharm, Moderna Inc., Pfizer Inc./BioNTech SE, AstraZeneca, CureVacAG, CanSino Biological Inc., Johnson & Johnson, Zydus Cadila, and Bharat Biotech, among others.
In November 2023, 64 investigational drugs were active in Phase 3 of clinical development.
Globally, the overall confirmed cases of COVID-19 reached more than 772 million as of November 22, 2023.
Fifty-eight COVID-19 vaccines were evaluated in Phase 3, 40 in Phase 2, 84 in Phase 1, and 199 in pre-clinical stages.
October 2023
There was a collaboration reported in October 2023 among COVID-19 diagnostics, therapeutics, and vaccines market.
In October 2023, the total number of treatment options was 226.
Key players evaluating Phase 3 vaccine and drug candidates included Biological E. Limited, SK Bioscience Co., Ltd., Abivax, AstraZeneca/the University of Oxford, Novavax, Sinopharm, Fulcrum, Therapeutics Moderna Inc., Pfizer Inc./BioNTech SE, AstraZeneca, CureVacAG, Insmed Inc., CanSino Biological Inc., Beijing Minhai Biotechnology, Johnson & Johnson, Zydus Cadila, and Bharat Biotech, among others.
In October 2023, 64 investigational drugs were active in Phase 3 of clinical development.
Globally, the overall confirmed cases of COVID-19 reached more than 771.5 million as of October 21, 2023.
Fifty-eight COVID-19 vaccines were evaluated in Phase 3, 40 in Phase 2, 84 in Phase 1, and 199 in pre-clinical stages.
COVID-19 Major Highlights of November 2023
U.S. FDA Grants Marketing Clearance to ACON Laboratories, Inc. for its COVID-19 Rapid Antigen Test
November 09, 2023:
The U.S. Food & Drug Administration (FDA) granted 510(k) marketing clearance to ACON Laboratories, Inc. for its COVID-19 Antigen Home Test Flowflex. This is the first FDA 510(k) for an over-the-counter (OTC) rapid antigen test for COVID-19. The Flowflex COVID-19 Antigen Home Test is indicated only for symptomatic individuals within the first six days after symptom onset. The company intends to start distribution of the test in 2024. The emergency use authorization (EUA) for the Flowflex COVID-19 Antigen Home Test has not been revoked, and ACON Laboratories, Inc. will continue to supply EUA test kits to meet the public demand for safe and easy home testing through the upcoming cough and cold season.
World Health Organization (WHO) Grants Emergency Use Listing (EUL) Status to COVID-19 Vaccine, Nuvaxovid XBB.1.5
November 28, 2023:
The World Health Organization (WHO) granted Emergency Use Listing (EUL) status to Novavax, Inc. for its COVID-19 vaccine (Nuvaxovid XBB.1.5) for active immunization to prevent COVID-19 in individuals aged 12 years and above. The EUL of Nuvaxovid XBB.1.5 enables expedited regulatory approvals in 194 WHO member states and UN procurement agencies, such as UNICEF, supporting broader access to a larger population. Nuvaxovid XBB.1.5 is the updated shot targeting the XBB lineage of the COVID-19 virus.
The Korean Ministry of Food and Drug Safety Grants Emergency Use Authorization to Updated Vaccine from Novavax
November 29, 2023:
The updated COVID-19 vaccine (NVX-CoV2601) produced by Novavax was given emergency use authorization (EUA) by the Ministry of Food and Drug Safety, Korea, marking the first approval of its kind in Asia. SK Bioscience intends to ship the improved version of the COVID-19 vaccine to South Korea by the end of 2023
Japan's Ministry of Health, Labour and Welfare (MHLW) Approves COVID-19 Vaccine Developed by CSL and Arcturus Therapeutics
November 29, 2023:
The self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, ARCT-154, developed by CSL and Arcturus Therapeutics, received approval from Japan's Ministry of Health, Labour and Welfare (MHLW). This vaccine is designated for initial vaccination and as a booster for individuals aged 18 years and older. The approval is based on positive Phase III clinical trial results conducted on 16,000 participants in Vietnam and a Phase III COVID-19 booster trial. In Japan, Seqirus, a subsidiary of CSL Limited entered into a distribution agreement with Meiji Seika Pharma for the supply of ARCT-154 in April 2023.
For more information about this newsletter visit
https://www.researchandmarkets.com/r/utrx7u
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Phase 3VaccineEmergency Use AuthorizationClinical ResultDrug Approval
14 Mar 2024
DUBLIN, March 13, 2024 /PRNewswire/ -- The "Royalty Rates in Pharmaceutical and Biotechnology Deals" report has been added to
ResearchAndMarkets.com's offering.
Royalty Rates in Pharmaceutical and Biotechnology Deals is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.
This report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of partnering deals disclosing royalty rates from 2010 to 2024.
The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2010. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2010.
Chapter 3 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal.
Chapter 4 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates.
Chapter 5 provides comprehensive and detailed access to deals which disclose a royalty rate since 2010 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate.
In addition the report includes a comprehensive deal directory listing of all deals where a royalty rate has been disclosed announced since 2010. Each listing is organized as a directory by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends in royalty rates in pharma and biotech deal making since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector.
Royalty Rates in Pharmaceutical and Biotechnology Deals provides the following benefits:
Understand royalty rate trends since 2010
Analysis of the structure of royalty clauses with real life case studies
Browse collaboration and licensing deals which reveal a royalty rate
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, therapy focus and technology type
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time
Analyzing actual contract agreements allows assessment of the following:
What are the precise royalty rates granted?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
1.1. What are royalties?
1.2. History of royalty rates
1.3. Royalties in pharmaceuticals and biotechnology
1.4. Royalties versus revenue share
1.5. Overview of the report
Chapter 2 - An overview of pharmaceutical and biotechnology royalty rates
2.1. Trends in royalty rates 2010 - 2024
2.2. How do revenue shares figure?
2.3. A review of recent literature
2.4. Royalty rates in the future
Chapter 3 - The royalty clause in pharmaceutical and biotechnology deals
3.1. Partnering agreement structure
3.2. Structure of a typical royalty clause
3.3. Example royalty clauses
3.3.1. Case study 1
3.3.2. Case study 2
3.3.3. Case study 3
3.3.4. Case study 4
Chapter 4 - Companies actively disclosing royalty rates
4.1. Most active companies in disclosing royalty rates
Chapter 5 - Royalty rate contract directory
Explore royalty rates within the deal contract document to gain greater insight
Deal directory
Deal Directory - Royalty rates in deals - by company A-Z
Deal Directory - Royalty rates in deals - by therapy area
Deal Directory - Royalty rates in deals - by stage of development at signing
Deal Directory - Royalty rates in deals - by technology type
Royalty rate references
Example royalty rate deal contract document
List of Figures
Figure 1: Trends in pharma and biotech royalty rates, 2010 - 2024
Figure 2: Components of the partnering deal structure
Figure 3: Components of the partnering royalty clause
Figure 4: Most active companies disclosing royalty rate 2010 - 2024
Figure 5: Licensing agreement for rhAAT - rEVO Biologics, LFB Biotechnologies
Companies Mentioned
2seventy bio
3a-diagnostics
3D Medicines
4SC
23andMe
Abbott Laboratories
Abbvie
Abeona Therapeutics
Ablynx
Abraxis BioScience
ABVC BioPharma
ACADIA Pharmaceuticals
Acceleron Pharma
Acelrx Pharmaceuticals
Acer Therapeutics
Acerus
Acrotech Biopharma
Actavis (acquired by Watson)
Active Biomaterials
Acura Pharmaceuticals
Adamis Pharmaceuticals
Adaptimmune
ADC Therapeutics
Adeona Pharmaceuticals
Adial Pharmaceuticals
Aditx Therapeutics
Adlai Nortye
Aduro BioTech
Advanced Dosage Forms
Advanz Pharma
Advaxis
Advirna
Aegerion Pharmaceutical
Aeglea BioTherapeutics
Aerie Pharmaceuticals
AEterna Zentaris
Aexon Labs
Affimed Therapeutics
Afritex Medical Products
AFT Pharmaceuticals
Agenus Bio
Agios Pharmaceuticals
Aguettant
AiBtl BioPharma
AIT Therapeutics
Akcea Therapeutics
Akebia Therapeutics
Albert Einstein College of Medicine
Alchemia
Alder Biopharmaceuticals
Alector
Alexion Pharmaceuticals
Alexza Pharmaceuticals
Alfasigma
Alfa Wassermann
Allergan
Allergan (name changed from Actavis)
Almirall
Alnylam Pharmaceuticals
Alora Pharmaceuticals
Alpha Biopharma
Alternavida
Altman Enterprises
AltrazealTrading
Altum Pharmaceuticals
Alvogen
Amarantus BioSciences
American Type Culture Collection (ATCC)
Amgen
Amherst Pharmaceuticals
Amorfix Life Sciences
Ampio Pharmaceuticals
Amryt Pharma
Amylin Pharmaceuticals
Amyris
AnaBios
AnaptysBio
AnGes MG
Angion Biomedica
AnnaMed
Antares Pharma
Antibe Therapeutics
Antigen Express
Applied Therapeutics
Apricus Biosciences
Aquestive Therapeutics
Aradigm
Aratana Therapeutics
Arcellx
Arch Pharmalabs
Arctic Vision
Arcturus Therapeutics
Arcus Biosciences
Ardelyx
Arena Pharmaceuticals
Arrowhead Pharmaceuticals
Artiva Biotherapeutics
Arvinas
Ascendis Pharma
Ascentage Pharma
Ashvattha Therapeutics
Assembly Biosciences
Astellas Pharma
Astellas Pharma Europe
Asterias Biotherapeutics
AstraZeneca
Athenex
Atossa Therapeutics
Atreca
Audeo Oncology
Augmenta
Aurigene Discovery Technologies
Aurinia Pharmaceuticals
Authentic Brands Group
AVEO Oncology
Avita Therapeutics
Avivagen
Axovant Gene Therapies
Axsome Therapeutics
Aytu BioPharma
Azaya Therapeutics
Azure Biotech
Baker Brothers Investments
BAKX Therapeutics
Baliopharm
BASF
Baxter International
Bayer Healthcare
Bayer Innovation
Baylor Research Institute
Beam Therapeutics
BeiGene
Beijing Defengrei Biotechnology
Belgian Volition
Bellerophon Therapeutics
Benitec Biopharma
Besins Healthcare
Beth Israel Deaconess Medical Center
BetterLife Pharma
Bharat Biotech
BIND Biosciences
BioCorRx
BioCryst Pharmaceuticals
Bioeq IP
Biogen
BioGene Technology
Biohaven Pharmaceuticals
BioInvent
BiolineRX
BioMarin Pharmaceutical
BioNovion
BioNTech
BioNxt Solutions
Biopharmex
BiopharmX
BioPorto
Bioprocess Capital Ventures
BioProspect
Biostem US
Biotech Investment
Biotechnology Value Fund
BioTime Acquisition
Bioton
Biovail
BioZone Laboratories
BioZone Pharmaceuticals
Blackstone
Bluebird Bio
Blueprint Medicines
BMV Medica
Boehringer Ingelheim
Bone Therapeutics
Braeburn Pharmaceuticals
BrainStorm Cell Therapeutics
Breathtec BioMedical
Brickell Biotech
BridgeBio Pharma
Bridge Biotherapeutics
Bristol-Myers Squibb
Caleco Pharma
Calico
Can-Fite BioPharma
Cancer Prevention Pharmaceuticals
Cannassure Therapeutics
CanniMed Therapeutics
Cann Pharmaceutical Australia
Canntab Therapeutics
Cannus Partners
Cantex Pharmaceuticals
Cara Therapeutics
Cardigant Medical
Cardium Therapeutics
CareFusion
Carna BioSciences
Cary Pharmaceuticals
CASI Pharmaceuticals
Castle Creek Biosciences
Catalent
CB2 Therapeutics
Celdara Medical
Celgene
Cell Cure Neurosciences
Cellvera
Cel Sci
Celyad
Cereal Ingredients
Cerebain Biotech
Cerus
CGA 369
cGreen
Chi-Med
Chiesi Farmaceutici
Chimerix
Chong Kun Dang
Chongqing Jingdong Pharmaceutical
Cimtech
Cipher Pharmaceuticals
Cipla
Circassia
Clal Biotech
Clalit Health Services
Clearmind Medicine
Clearside Biomedical
Clemson University
Cleveland BioLabs
Clinigen
CMIC
CNS Pharmaceuticals
Cocrystal Pharma
Coeptis Pharmaceuticals
CohBar
Cohen-McNiece Foundation
Coherus Biosciences
Colby Pharmaceuticals
Collegium Pharmaceuticals
Columbia Laboratories
Columbia University
Common Sense
Conatus Pharmaceuticals
Concile
Consilient Health
ContraFect
Coronado Biosciences
Cosmofix
Cosmo Pharmaceuticals
Coya Therapeutics
CRISPR Therapeutics
Crossject
Crucell
CSL
CTI BioPharma
CTT Pharmaceutical
Cullinan Oncology
Cumberland Pharmaceuticals
Cures Within Reach
CureTech
Curis
Currax Pharmaceuticals
CURx Pharmaceuticals
Cutanea Life Sciences
Cybin
CymaBay Therapeutics
Cypress Bioscience
Cytodyn
Cytokinetics
Cytori Therapeutics
Daewoong Pharmaceutical
Daiichi Sankyo
Dana-Farber Cancer Institute
Dance Biopharm
DAS Therapeutics
Defiante Farmaceutica
Denali Therapeutics
DepoMed
Derma Sciences
Dermavant Sciences
Dermin
Dianomi Therapeutics
Dicerna Pharmaceuticals
DNA Biomedical Solutions
Dr. Falk Pharma
Dr. Reddy's Laboratories
Dragonfly Therapeutics
DRI Capital
Drugs for Neglected Diseases Initiative
DS Healthcare
Duke University
Dyax
Eagle Pharmaceuticals
Eagle Pharmaceuticals (US)
Easton Pharmaceuticals
Echo Therapeutics
Ecology Coatings
Eczacibasi Pharmaceuticals
Eddingpharm
Egalet
Eisai
Elencee
Eli Lilly
Elite Pharmaceuticals
Emergent BioSolutions
Emory University
Enalare Therapeutics
Endocyte
Endo Pharmaceuticals
EnGeneIC
Enochian Biosciences
Entera Bio
Entest BioMedical
EnWave
Epizyme
Epocal
Esperion Therapeutics
Eternity Healthcare
Eton Pharmaceuticals
Eureka Genomics
EUSA Pharma
Evolva
Ewopharma
Exact Sciences
Exelixis
ExScientia
Eyevance
Fairview Health System
FasTrack Pharmaceuticals
Ferozsons Laboratories
Ferring Pharmaceuticals
Fibrocell Science
Foghorn Therapeutics
Forest Laboratories
Fosun Pharmaceutical
Fox Chase Chemical Diversity Center
Fresenius Kabi Pharmaceuticals
FSD Pharma
Fusion Pharmaceuticals
FusionVax
Galapagos
Galmed Pharmaceuticals
GE Healthcare
Genentech
Generex Biotechnology
Genevant Sciences
Genexine
Genfit
Genmab
Gentium
Genzyme
Geron
Gilead Sciences
Glaukos
Glenmark Generics Inc USA
Glenmark Pharmaceuticals
Goldfinch Bio
Government of Israel
GPCR Therapeutics
Gravocore
Grifols
GSK
GT Biopharma
Hai Kang Life
Hail First Pharma
Hainan Sihuan Pharmaceutical
Halo Labs
Halozyme Therapeutics
Hansen Medical
Health Canada
Healthcare Royalty Partners
Health Discovery
Heartseed
Heat Biologics
Hefei Life Science
Hefei Tianhui Incubation of Technologies
HekaBio
Helsinn Therapeutics
HemoCleanse
Hemogenyx
HemPup
Henlius Biotech
Hetero Labs
HIBM Research Group
Hikma Pharmaceuticals
Hoffmann La Roche
Hollister Biosciences
Hookipa Pharma
Horizon Pharma Inc
Huadong Medicine
HyperGenomics
I-mab
Icahn School of Medicine at Mount Sinai
Ice + Jam
Iconovo
IDC-GP Pharm
IDEAYA Biosciences
Idera Pharmaceuticals
Idorsia
Idun Pharmaceuticals
IGM Biosciences
iMetabolic Biopharma
Immugenyx
Immunic
ImmunityBio
Immunomedics
Immunomic Therapeutics
Immunovative Therapies
ImmVira
Impax Laboratories
Imprimis Pharmaceuticals
In4Derm
iNAP
Incannex Healthcare
Incuron
Incyte
Indiana University
Infinity Pharmaceuticals
InflaRx
Inhibitor Therapeutics
Innate Pharma
Innocoll
Innovate Biopharmaceuticals
Innovation Pharmaceuticals
Innovent Biologics
Innovet
Innovus Pharmaceuticals
INO Therapeutics
Inspiration Biopharmaceuticals
Instrumentation Laboratory
IntelGenx
Intellia Therapeutics
IntelliCell BioSciences
Intellikine
Internet Marketing Consortium
Intrexon
Intuitive Surgical
Invekra
Inverness Medical Innovations
Ionis Pharmaceuticals
Ipsen
Iroko Pharmaceuticals
Ironwood Pharmaceuticals
Israeli National Authority for Technological Innovation
Itrom Pharmaceutical Group
Ivantis
Jaguar Health
Janssen Biotech
Janssen Pharmaceuticals
Jazz Pharmaceuticals
JFC Technologies
Jiangsu Alphamab
Jiangsu Lianhuan Pharmaceuticals
Jiangsu NHWA Pharmaceutical
Ji Xing Pharmaceuticals
John Morley Foods
Joincare Pharmaceutical
Journey Medical
Jubilant Life Sciences
Jumpcan Pharmaceutical
Juniper Pharmaceuticals
Junshi Biosciences
Jupiter Wellness
Juventas Therapeutics
K2M
Kadmon Pharmaceuticals
Kaken Pharmaceutical
Kalbe Genexine Biologics
KaloBios Pharmaceuticals
Karveer Meditech
KemPharm
Kensey Nash
Kieran Murphy
Kinetic Concepts
Kiniksa Pharmaceuticals
Kintor
Kiromic Biopharma
Kite Pharma
Kitov Pharma
Klaria
Klinge Biopharma
Knighton Foods
Knight Therapeutics
Kodiak Sciences
Kowa
Kraig Biocraft Laboratories
KVK-Tech
Kwang Dong Pharmaceutical
Kymera Therapeutics
Kyowa Hakko Kirin
Kyverna Therapeutics
L1 Systems
Laboratories Acbel
Lantheus Holding
Launch Therapeutics
Lee Moffitt Cancer Center
Legend Biotech
LegoChem Biosciences
Level Brands
LFB Biotechnologies
Lifestyle Delivery Systems
Ligand Pharmaceuticals
Lineage Cell Therapeutics
Link Health
Lipidor
Lipocine
Lixte Biotechnology
Lorna Linda University
Lotus Pharmaceuticals
Loxo Oncology
Lubrizol
Lumenis
Lundbeck
Lung Therapeutics
MabCure
Macrogenics
Magenta Therapeutics
MainPointe
Mallinckrodt Pharmaceuticals
Marvanal
Marv Enterprises
Massachusetts General Hospital
Matrix Biomed
Mayne Pharma
McComb Foundation
McEwen Centre for Regenerative Medicine
Meda
Medica
Medica Avante
Medical Technologies Innovation Asia
Medice Arzneimittel Putter
Medicines Patent Pool Foundation
Medicox
MediGene
Medigus
MedImmune
Medison Pharma
Medivation
Medivir
Medovex
MEI Pharma
Melmed
Memory Dx
Mercer University
Merck and Co
Merck KGaA
Merck Serono
Merus
Methodist Hospital Houston
Micromet
Mikah Pharma
Millennium
Mimi's Rock
Mindset Pharma
Ministry of Health
Labor and Welfare
MiNK Therapeutics
Miraculins
Miralogx
Mira Pharmaceuticals
Miromatrix Medical
Mitsubishi Tanabe Pharma
Moderna
Modis Therapeutics
Moleculin Biotech
Mologen
Momenta Pharmaceuticals
Monash University
Monopar Therapeutics
Morgan Stanley
MorphoSys
Mount Sinai Health System
MultiCell Immunotherapeutics
Munich Leukemia Laboratory
Mylan Laboratories
Mylan Pharmaceuticals
Myovant Sciences
NanoVibronix
NanoViricides
NantCell
NantKwest
Nantong Jinghua Pharmaceutical
NantWorks
Napo Pharmaceuticals
Natac Biotech
Natco Pharmaceuticals
National Green Biomed
Nektar Therapeutics
Neogenomics
Neotope
Nephrogenex
Nephros
Nestle Health Science
Neuraxpharm
Neurocrine Biosciences
NeuroRx
NeuroSigma
NeuroVive Pharmaceutical
NeuroVive Pharmaceutical Asia
NewLeaf Brands
Newsoara Biopharma
New York University
NexMed
NextCure
Nextleaf Solutions
Nexvet
NGM Biopharmaceuticals
Nicox
Nkarta Therapeutics
NLS Pharmaceutics
Nordic Bioscience
Norgine
NorthStar Medical Radioisotopes
Notable Labs
Novadaq Technologies
NovaDel Pharma
Novan
Novan Therapeutics
Novartis
Novartis Vaccines and Diagnostics
Novocure
Novo Nordisk
Novus Biologicals
NRx Pharmaceuticals
Nucorion
Numab
Nunzi Pharmaceutical
Nurix Therapeutics
Nutech Medical
NutraOrigin
NXTGEN
Nymox Pharmaceutical
Oberland Capital
Ocugen
Oculus Innovative Sciences
Ocumension Therapeutics
Omeros
Oncologie
Oncolytics Biotech
OncoMed Pharmaceuticals
Onconova Therapeutics
Onegevity
One Way Liver Genomics (OWL)
ONK Therapeutics
Ono Pharmaceutical
Onxeo
Onyx Pharmaceuticals
Opexa Therapeutics
Opthea
OptiBiotix
OptiNose
Oragenics
Oramed Pharmaceuticals
Orexigen Therapeutics
Organovo
Orgenesis
Orion
Orox Pharmaceuticals
OrthoCyte
Otsuka
OvaMed
Ovid Therapeutics
Oxford BioMedica
Oxis Biotech
Oxygen Biotherapeutics
OxySure Systems
Oyster Point Pharma
Pan-Provincial Vaccine Enterprise
Parnell Pharmaceuticals
Par Pharmaceutical
PDL BioPharma
PDS Biotechnology
Penwest Pharmaceuticals
Pernix Therapeutics
Perugia University
Pfenex
Pfizer
Pharmacyclics
PharmaCyte Biotech
PharmaMar
PharmaNova
Pharmastrip
Philogen
Phosphagenics
Photocure ASA
Phusion Laboratoies
Phyto Nutricare
Pipex Pharmaceuticals
Plandai Biotechnology
Pluristem Therapeutics
POINT Biopharma
Portola Pharmaceuticals
Poseida Therapeutics
Pozen
PreMD
Premier Biomedical
Professional Compounding Centers of America
Progenics Pharmaceuticals
Prometic Life Sciences
ProQR Therapeutics
Prosidion
Protagonist Therapeutics
Protalix BioTherapeutics
Proteonomix
Prothena
ProtoKinetix
Pulmatrix
Puma Biotechnology
QED Therapeutics
QRxPharma
Quick Med Technologies
Quigley Corporation
Quoin Pharmaceuticals
Rayner Surgical
Reata Pharmaceuticals
Recordati
Recro Pharma
RedHill Biopharma
Reedy Creek Investments
RegenaStem
Regeneron Pharmaceuticals
Regenxbio
Regnum
Relay Therapeutics
Relief Therapeutics
Relmada Therapeutics
RenalytixAI
ReNeuron
Repare Therapeutics
Replicel Life Sciences
Repligen
Reprise Biomedical
Resarci Therapeutics
Retrophin
rEVO Biologics
Revolution Medicines
Rigel Pharmaceuticals
RNL Bio
Roche
Rockefeller University
Roivant Sciences
Royalty Pharma
RST Biomedikal Sanayi
Ruthigen
RXi Pharmaceuticals
S2 Therapeutics
SACCO
Sagard Healthcare Royalty Partners
Sage Therapeutics
Salix Pharmaceuticals
Sam Amer
Sanara MedTech
Sandoz
Sanofi
Sanofi-Aventis
Sanofi-Pasteur
Sanpellegrino Cosmetics
Santarus
Santen Pharmaceutical
Sanuwave Health
SA Pathology
Sapientia Pharmaceuticals
Sarepta Therapeutics
Schrodinger
Scopus BioPharma
Seagen
Seattle Genetics
Seelos Therapeutics
Sekris Biomedical
Senetek
Senior Paradise
Sensory Cloud
Seqirus
Seres Therapeutics
Sermonix Pharmaceutical
Sesen Bio
SevenScore Pharmaceuticals
Shanghai Pharmaceuticals Holdings
Sheba Medical Center
Shenzhen BioScien Pharmaceuticals
Shield Therapeutics
Shionogi
Shire Pharmaceuticals
Shore Therapeutics
Siemens Healthcare Diagnostics
Sigma-Tau
Sinclair Pharmaceuticals
Sinobiopharma
Sinopharm
Sio Gene Therapies
Skinvera
Skyline Diagnostics
Solarvest BioEnergy
Soliance
Soligenix
Sonoma BioTherapeutics
Sorrento Therapeutics
Spectranetics
Spencer Pharmaceutical
Spinal USA
St. Jude Children's Research Hospital
STADA Arzneimittel
Staidson (Beijing) BioPharmaceuticals
Stanford University
Stealth BioTherapeutics
Stellar Biotechnologies
St Jude Medical
Stoke Therapeutics
Strongbridge Biopharma
Sucampo AG
SUDA Pharmaceuticals
Sumitomo Dainippon Pharma
Sunesis Pharmaceuticals
Sunovion Pharmaceuticals
Sun Pharmaceutical
SuperNova Diagnostics
Sutro Biopharma
Swedish Orphan Biovitrum
SymBio Pharmaceuticals
Symbollon
Syndax Pharmaceuticals
Synergy Strips
Syntopix
Tactical Relief
Taiba
TaiGen Biotechnology
Taiho
Takeda Pharmaceutical
Talaris Therapeutics
Tango Therapeutics
Target Group
Tauriga Sciences
TB Alliance
TearLab
Technion Research and Development Foundation
Teijin
Telomir Pharmaceuticals
Tesaro
Tetra Bio-Pharma
TetraLogic Pharmaceuticals
Teva Pharmaceutical Industries
Texas A&M University
Texas Heart Institute
TFF Pharmaceuticals
TG Therapeutics
Therakine
TherapeuticsMD
Theravance
Theravance Biopharma
The Regents of the University of California
Thorne Research
Threshold Pharmaceuticals
TiGenix
Tilray
Titterington Veterinary Services
Tiziana Life Sciences
Tocagen
TONIX Pharmaceuticals
Torii Pharmaceutical
TRACON Pharmaceuticals
Tramorgan
Transgene
Travere Therapeutics
Trellis Bioscience
Trevena
Trimedyne
Trimeris
TrovaGene
TTFactor
Tufts University
Turnstone Biologics
Tyme Technologies
Ultragenyx Pharmaceuticals
Uluru
Unigene Laboratories
UniQure
Universal Cells
University College Dublin
University Health Network
University of Alberta
University of California
University of Central Florida Research Foundation
University of Colorado
University of Florida Research Foundation
University of Geneva
University of Louisville
University of Missouri
University of Notre of Dame
University of Pennsylvania
University of Texas
University of Virginia
University of Western Sydney
University of Zurich
UOP
Uppsalagruppen Medical
Upstream Peripheral Technologies
UroGen Pharma
Valeant Pharmaceuticals
ValiPharma
Valneva
Valor Biotherapeutics
Vanderbilt University
Vasomune Therapeutics
Vaxent
VBL Therapeutics
Veloxis Pharmaceuticals
Veracyte
Verenium
Verity Pharmaceuticals
VeroScience
Vertex Pharmaceuticals
Vida Concepts
Vifor Pharma
ViiV Healthcare
Virbac
Viropharma
VistaGen Therapeutics
Vividion Therapeutics
Vivus
VolitionRX
Voronoi
Voyager Therapeutics
Vyera Pharmaceuticals
VYNE Therapeutics
Vyrix Pharmaceuticals
Watson Pharmaceuticals
WAVE Life Sciences
Wigen Biomedicine
Wisconsin Alumni Research Foundation
World Class Extractions
WPD Pharmaceuticals
WUGEN
Xbrane Bioscience
Xencor
Xlife Sciences
XPhyto Therapeutics
XTL Biopharmaceuticals
Xynomic Pharmaceuticals
Yale University
Yeda Research and Development Company
Yeugnam University
Yissum Research Development
ZAI Laboratory
Zalicus
Zenitech
Zenith Epigenetics
Ziopharm Oncology
Zogenix
ZS Pharma
Zymeworks
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo:
SOURCE Research and Markets
VaccineAcquisition
13 Mar 2024
DUBLIN--(
BUSINESS WIRE
)--The
"Royalty Rates in Pharmaceutical and Biotechnology Deals"
report has been added to
ResearchAndMarkets.com's
offering.
Royalty Rates in Pharmaceutical and Biotechnology Deals
is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.
This report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of partnering deals disclosing royalty rates from 2010 to 2024.
The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2010. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2010.
Chapter 3 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal.
Chapter 4 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates.
Chapter 5 provides comprehensive and detailed access to deals which disclose a royalty rate since 2010 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate.
In addition the report includes a comprehensive deal directory listing of all deals where a royalty rate has been disclosed announced since 2010. Each listing is organized as a directory by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends in royalty rates in pharma and biotech deal making since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector.
Royalty Rates in Pharmaceutical and Biotechnology Deals provides the following benefits:
Understand royalty rate trends since 2010
Analysis of the structure of royalty clauses with real life case studies
Browse collaboration and licensing deals which reveal a royalty rate
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, therapy focus and technology type
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time
Analyzing actual contract agreements allows assessment of the following:
What are the precise royalty rates granted?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
1.1. What are royalties?
1.2. History of royalty rates
1.3. Royalties in pharmaceuticals and biotechnology
1.4. Royalties versus revenue share
1.5. Overview of the report
Chapter 2 - An overview of pharmaceutical and biotechnology royalty rates
2.1. Trends in royalty rates 2010 - 2024
2.2. How do revenue shares figure?
2.3. A review of recent literature
2.4. Royalty rates in the future
Chapter 3 - The royalty clause in pharmaceutical and biotechnology deals
3.1. Partnering agreement structure
3.2. Structure of a typical royalty clause
3.3. Example royalty clauses
3.3.1. Case study 1
3.3.2. Case study 2
3.3.3. Case study 3
3.3.4. Case study 4
Chapter 4 - Companies actively disclosing royalty rates
4.1. Most active companies in disclosing royalty rates
Chapter 5 - Royalty rate contract directory
Explore royalty rates within the deal contract document to gain greater insight
Deal directory
Deal Directory - Royalty rates in deals - by company A-Z
Deal Directory - Royalty rates in deals - by therapy area
Deal Directory - Royalty rates in deals - by stage of development at signing
Deal Directory - Royalty rates in deals - by technology type
Royalty rate references
Example royalty rate deal contract document
List of Figures
Figure 1: Trends in pharma and biotech royalty rates, 2010 - 2024
Figure 2: Components of the partnering deal structure
Figure 3: Components of the partnering royalty clause
Figure 4: Most active companies disclosing royalty rate 2010 - 2024
Figure 5: Licensing agreement for rhAAT - rEVO Biologics, LFB Biotechnologies
Companies Mentioned
2seventy bio
3a-diagnostics
3D Medicines
4SC
23andMe
Abbott Laboratories
Abbvie
Abeona Therapeutics
Ablynx
Abraxis BioScience
ABVC BioPharma
ACADIA Pharmaceuticals
Acceleron Pharma
Acelrx Pharmaceuticals
Acer Therapeutics
Acerus
Acrotech Biopharma
Actavis (acquired by Watson)
Active Biomaterials
Acura Pharmaceuticals
Adamis Pharmaceuticals
Adaptimmune
ADC Therapeutics
Adeona Pharmaceuticals
Adial Pharmaceuticals
Aditx Therapeutics
Adlai Nortye
Aduro BioTech
Advanced Dosage Forms
Advanz Pharma
Advaxis
Advirna
Aegerion Pharmaceutical
Aeglea BioTherapeutics
Aerie Pharmaceuticals
AEterna Zentaris
Aexon Labs
Affimed Therapeutics
Afritex Medical Products
AFT Pharmaceuticals
Agenus Bio
Agios Pharmaceuticals
Aguettant
AiBtl BioPharma
AIT Therapeutics
Akcea Therapeutics
Akebia Therapeutics
Albert Einstein College of Medicine
Alchemia
Alder Biopharmaceuticals
Alector
Alexion Pharmaceuticals
Alexza Pharmaceuticals
Alfasigma
Alfa Wassermann
Allergan
Allergan (name changed from Actavis)
Almirall
Alnylam Pharmaceuticals
Alora Pharmaceuticals
Alpha Biopharma
Alternavida
Altman Enterprises
AltrazealTrading
Altum Pharmaceuticals
Alvogen
Amarantus BioSciences
American Type Culture Collection (ATCC)
Amgen
Amherst Pharmaceuticals
Amorfix Life Sciences
Ampio Pharmaceuticals
Amryt Pharma
Amylin Pharmaceuticals
Amyris
AnaBios
AnaptysBio
AnGes MG
Angion Biomedica
AnnaMed
Antares Pharma
Antibe Therapeutics
Antigen Express
Applied Therapeutics
Apricus Biosciences
Aquestive Therapeutics
Aradigm
Aratana Therapeutics
Arcellx
Arch Pharmalabs
Arctic Vision
Arcturus Therapeutics
Arcus Biosciences
Ardelyx
Arena Pharmaceuticals
Arrowhead Pharmaceuticals
Artiva Biotherapeutics
Arvinas
Ascendis Pharma
Ascentage Pharma
Ashvattha Therapeutics
Assembly Biosciences
Astellas Pharma
Astellas Pharma Europe
Asterias Biotherapeutics
AstraZeneca
Athenex
Atossa Therapeutics
Atreca
Audeo Oncology
Augmenta
Aurigene Discovery Technologies
Aurinia Pharmaceuticals
Authentic Brands Group
AVEO Oncology
Avita Therapeutics
Avivagen
Axovant Gene Therapies
Axsome Therapeutics
Aytu BioPharma
Azaya Therapeutics
Azure Biotech
Baker Brothers Investments
BAKX Therapeutics
Baliopharm
BASF
Baxter International
Bayer Healthcare
Bayer Innovation
Baylor Research Institute
Beam Therapeutics
BeiGene
Beijing Defengrei Biotechnology
Belgian Volition
Bellerophon Therapeutics
Benitec Biopharma
Besins Healthcare
Beth Israel Deaconess Medical Center
BetterLife Pharma
Bharat Biotech
BIND Biosciences
BioCorRx
BioCryst Pharmaceuticals
Bioeq IP
Biogen
BioGene Technology
Biohaven Pharmaceuticals
BioInvent
BiolineRX
BioMarin Pharmaceutical
BioNovion
BioNTech
BioNxt Solutions
Biopharmex
BiopharmX
BioPorto
Bioprocess Capital Ventures
BioProspect
Biostem US
Biotech Investment
Biotechnology Value Fund
BioTime Acquisition
Bioton
Biovail
BioZone Laboratories
BioZone Pharmaceuticals
Blackstone
Bluebird Bio
Blueprint Medicines
BMV Medica
Boehringer Ingelheim
Bone Therapeutics
Braeburn Pharmaceuticals
BrainStorm Cell Therapeutics
Breathtec BioMedical
Brickell Biotech
BridgeBio Pharma
Bridge Biotherapeutics
Bristol-Myers Squibb
Caleco Pharma
Calico
Can-Fite BioPharma
Cancer Prevention Pharmaceuticals
Cannassure Therapeutics
CanniMed Therapeutics
Cann Pharmaceutical Australia
Canntab Therapeutics
Cannus Partners
Cantex Pharmaceuticals
Cara Therapeutics
Cardigant Medical
Cardium Therapeutics
CareFusion
Carna BioSciences
Cary Pharmaceuticals
CASI Pharmaceuticals
Castle Creek Biosciences
Catalent
CB2 Therapeutics
Celdara Medical
Celgene
Cell Cure Neurosciences
Cellvera
Cel Sci
Celyad
Cereal Ingredients
Cerebain Biotech
Cerus
CGA 369
cGreen
Chi-Med
Chiesi Farmaceutici
Chimerix
Chong Kun Dang
Chongqing Jingdong Pharmaceutical
Cimtech
Cipher Pharmaceuticals
Cipla
Circassia
Clal Biotech
Clalit Health Services
Clearmind Medicine
Clearside Biomedical
Clemson University
Cleveland BioLabs
Clinigen
CMIC
CNS Pharmaceuticals
Cocrystal Pharma
Coeptis Pharmaceuticals
CohBar
Cohen-McNiece Foundation
Coherus Biosciences
Colby Pharmaceuticals
Collegium Pharmaceuticals
Columbia Laboratories
Columbia University
Common Sense
Conatus Pharmaceuticals
Concile
Consilient Health
ContraFect
Coronado Biosciences
Cosmofix
Cosmo Pharmaceuticals
Coya Therapeutics
CRISPR Therapeutics
Crossject
Crucell
CSL
CTI BioPharma
CTT Pharmaceutical
Cullinan Oncology
Cumberland Pharmaceuticals
Cures Within Reach
CureTech
Curis
Currax Pharmaceuticals
CURx Pharmaceuticals
Cutanea Life Sciences
Cybin
CymaBay Therapeutics
Cypress Bioscience
Cytodyn
Cytokinetics
Cytori Therapeutics
Daewoong Pharmaceutical
Daiichi Sankyo
Dana-Farber Cancer Institute
Dance Biopharm
DAS Therapeutics
Defiante Farmaceutica
Denali Therapeutics
DepoMed
Derma Sciences
Dermavant Sciences
Dermin
Dianomi Therapeutics
Dicerna Pharmaceuticals
DNA Biomedical Solutions
Dr. Falk Pharma
Dr. Reddy's Laboratories
Dragonfly Therapeutics
DRI Capital
Drugs for Neglected Diseases Initiative
DS Healthcare
Duke University
Dyax
Eagle Pharmaceuticals
Eagle Pharmaceuticals (US)
Easton Pharmaceuticals
Echo Therapeutics
Ecology Coatings
Eczacibasi Pharmaceuticals
Eddingpharm
Egalet
Eisai
Elencee
Eli Lilly
Elite Pharmaceuticals
Emergent BioSolutions
Emory University
Enalare Therapeutics
Endocyte
Endo Pharmaceuticals
EnGeneIC
Enochian Biosciences
Entera Bio
Entest BioMedical
EnWave
Epizyme
Epocal
Esperion Therapeutics
Eternity Healthcare
Eton Pharmaceuticals
Eureka Genomics
EUSA Pharma
Evolva
Ewopharma
Exact Sciences
Exelixis
ExScientia
Eyevance
Fairview Health System
FasTrack Pharmaceuticals
Ferozsons Laboratories
Ferring Pharmaceuticals
Fibrocell Science
Foghorn Therapeutics
Forest Laboratories
Fosun Pharmaceutical
Fox Chase Chemical Diversity Center
Fresenius Kabi Pharmaceuticals
FSD Pharma
Fusion Pharmaceuticals
FusionVax
Galapagos
Galmed Pharmaceuticals
GE Healthcare
Genentech
Generex Biotechnology
Genevant Sciences
Genexine
Genfit
Genmab
Gentium
Genzyme
Geron
Gilead Sciences
Glaukos
Glenmark Generics Inc USA
Glenmark Pharmaceuticals
Goldfinch Bio
Government of Israel
GPCR Therapeutics
Gravocore
Grifols
GSK
GT Biopharma
Hai Kang Life
Hail First Pharma
Hainan Sihuan Pharmaceutical
Halo Labs
Halozyme Therapeutics
Hansen Medical
Health Canada
Healthcare Royalty Partners
Health Discovery
Heartseed
Heat Biologics
Hefei Life Science
Hefei Tianhui Incubation of Technologies
HekaBio
Helsinn Therapeutics
HemoCleanse
Hemogenyx
HemPup
Henlius Biotech
Hetero Labs
HIBM Research Group
Hikma Pharmaceuticals
Hoffmann La Roche
Hollister Biosciences
Hookipa Pharma
Horizon Pharma Inc
Huadong Medicine
HyperGenomics
I-mab
Icahn School of Medicine at Mount Sinai
Ice + Jam
Iconovo
IDC-GP Pharm
IDEAYA Biosciences
Idera Pharmaceuticals
Idorsia
Idun Pharmaceuticals
IGM Biosciences
iMetabolic Biopharma
Immugenyx
Immunic
ImmunityBio
Immunomedics
Immunomic Therapeutics
Immunovative Therapies
ImmVira
Impax Laboratories
Imprimis Pharmaceuticals
In4Derm
iNAP
Incannex Healthcare
Incuron
Incyte
Indiana University
Infinity Pharmaceuticals
InflaRx
Inhibitor Therapeutics
Innate Pharma
Innocoll
Innovate Biopharmaceuticals
Innovation Pharmaceuticals
Innovent Biologics
Innovet
Innovus Pharmaceuticals
INO Therapeutics
Inspiration Biopharmaceuticals
Instrumentation Laboratory
IntelGenx
Intellia Therapeutics
IntelliCell BioSciences
Intellikine
Internet Marketing Consortium
Intrexon
Intuitive Surgical
Invekra
Inverness Medical Innovations
Ionis Pharmaceuticals
Ipsen
Iroko Pharmaceuticals
Ironwood Pharmaceuticals
Israeli National Authority for Technological Innovation
Itrom Pharmaceutical Group
Ivantis
Jaguar Health
Janssen Biotech
Janssen Pharmaceuticals
Jazz Pharmaceuticals
JFC Technologies
Jiangsu Alphamab
Jiangsu Lianhuan Pharmaceuticals
Jiangsu NHWA Pharmaceutical
Ji Xing Pharmaceuticals
John Morley Foods
Joincare Pharmaceutical
Journey Medical
Jubilant Life Sciences
Jumpcan Pharmaceutical
Juniper Pharmaceuticals
Junshi Biosciences
Jupiter Wellness
Juventas Therapeutics
K2M
Kadmon Pharmaceuticals
Kaken Pharmaceutical
Kalbe Genexine Biologics
KaloBios Pharmaceuticals
Karveer Meditech
KemPharm
Kensey Nash
Kieran Murphy
Kinetic Concepts
Kiniksa Pharmaceuticals
Kintor
Kiromic Biopharma
Kite Pharma
Kitov Pharma
Klaria
Klinge Biopharma
Knighton Foods
Knight Therapeutics
Kodiak Sciences
Kowa
Kraig Biocraft Laboratories
KVK-Tech
Kwang Dong Pharmaceutical
Kymera Therapeutics
Kyowa Hakko Kirin
Kyverna Therapeutics
L1 Systems
Laboratories Acbel
Lantheus Holding
Launch Therapeutics
Lee Moffitt Cancer Center
Legend Biotech
LegoChem Biosciences
Level Brands
LFB Biotechnologies
Lifestyle Delivery Systems
Ligand Pharmaceuticals
Lineage Cell Therapeutics
Link Health
Lipidor
Lipocine
Lixte Biotechnology
Lorna Linda University
Lotus Pharmaceuticals
Loxo Oncology
Lubrizol
Lumenis
Lundbeck
Lung Therapeutics
MabCure
Macrogenics
Magenta Therapeutics
MainPointe
Mallinckrodt Pharmaceuticals
Marvanal
Marv Enterprises
Massachusetts General Hospital
Matrix Biomed
Mayne Pharma
McComb Foundation
McEwen Centre for Regenerative Medicine
Meda
Medica
Medica Avante
Medical Technologies Innovation Asia
Medice Arzneimittel Putter
Medicines Patent Pool Foundation
Medicox
MediGene
Medigus
MedImmune
Medison Pharma
Medivation
Medivir
Medovex
MEI Pharma
Melmed
Memory Dx
Mercer University
Merck and Co
Merck KGaA
Merck Serono
Merus
Methodist Hospital Houston
Micromet
Mikah Pharma
Millennium
Mimi's Rock
Mindset Pharma
Ministry of Health
Labor and Welfare
MiNK Therapeutics
Miraculins
Miralogx
Mira Pharmaceuticals
Miromatrix Medical
Mitsubishi Tanabe Pharma
Moderna
Modis Therapeutics
Moleculin Biotech
Mologen
Momenta Pharmaceuticals
Monash University
Monopar Therapeutics
Morgan Stanley
MorphoSys
Mount Sinai Health System
MultiCell Immunotherapeutics
Munich Leukemia Laboratory
Mylan Laboratories
Mylan Pharmaceuticals
Myovant Sciences
NanoVibronix
NanoViricides
NantCell
NantKwest
Nantong Jinghua Pharmaceutical
NantWorks
Napo Pharmaceuticals
Natac Biotech
Natco Pharmaceuticals
National Green Biomed
Nektar Therapeutics
Neogenomics
Neotope
Nephrogenex
Nephros
Nestle Health Science
Neuraxpharm
Neurocrine Biosciences
NeuroRx
NeuroSigma
NeuroVive Pharmaceutical
NeuroVive Pharmaceutical Asia
NewLeaf Brands
Newsoara Biopharma
New York University
NexMed
NextCure
Nextleaf Solutions
Nexvet
NGM Biopharmaceuticals
Nicox
Nkarta Therapeutics
NLS Pharmaceutics
Nordic Bioscience
Norgine
NorthStar Medical Radioisotopes
Notable Labs
Novadaq Technologies
NovaDel Pharma
Novan
Novan Therapeutics
Novartis
Novartis Vaccines and Diagnostics
Novocure
Novo Nordisk
Novus Biologicals
NRx Pharmaceuticals
Nucorion
Numab
Nunzi Pharmaceutical
Nurix Therapeutics
Nutech Medical
NutraOrigin
NXTGEN
Nymox Pharmaceutical
Oberland Capital
Ocugen
Oculus Innovative Sciences
Ocumension Therapeutics
Omeros
Oncologie
Oncolytics Biotech
OncoMed Pharmaceuticals
Onconova Therapeutics
Onegevity
One Way Liver Genomics (OWL)
ONK Therapeutics
Ono Pharmaceutical
Onxeo
Onyx Pharmaceuticals
Opexa Therapeutics
Opthea
OptiBiotix
OptiNose
Oragenics
Oramed Pharmaceuticals
Orexigen Therapeutics
Organovo
Orgenesis
Orion
Orox Pharmaceuticals
OrthoCyte
Otsuka
OvaMed
Ovid Therapeutics
Oxford BioMedica
Oxis Biotech
Oxygen Biotherapeutics
OxySure Systems
Oyster Point Pharma
Pan-Provincial Vaccine Enterprise
Parnell Pharmaceuticals
Par Pharmaceutical
PDL BioPharma
PDS Biotechnology
Penwest Pharmaceuticals
Pernix Therapeutics
Perugia University
Pfenex
Pfizer
Pharmacyclics
PharmaCyte Biotech
PharmaMar
PharmaNova
Pharmastrip
Philogen
Phosphagenics
Photocure ASA
Phusion Laboratoies
Phyto Nutricare
Pipex Pharmaceuticals
Plandai Biotechnology
Pluristem Therapeutics
POINT Biopharma
Portola Pharmaceuticals
Poseida Therapeutics
Pozen
PreMD
Premier Biomedical
Professional Compounding Centers of America
Progenics Pharmaceuticals
Prometic Life Sciences
ProQR Therapeutics
Prosidion
Protagonist Therapeutics
Protalix BioTherapeutics
Proteonomix
Prothena
ProtoKinetix
Pulmatrix
Puma Biotechnology
QED Therapeutics
QRxPharma
Quick Med Technologies
Quigley Corporation
Quoin Pharmaceuticals
Rayner Surgical
Reata Pharmaceuticals
Recordati
Recro Pharma
RedHill Biopharma
Reedy Creek Investments
RegenaStem
Regeneron Pharmaceuticals
Regenxbio
Regnum
Relay Therapeutics
Relief Therapeutics
Relmada Therapeutics
RenalytixAI
ReNeuron
Repare Therapeutics
Replicel Life Sciences
Repligen
Reprise Biomedical
Resarci Therapeutics
Retrophin
rEVO Biologics
Revolution Medicines
Rigel Pharmaceuticals
RNL Bio
Roche
Rockefeller University
Roivant Sciences
Royalty Pharma
RST Biomedikal Sanayi
Ruthigen
RXi Pharmaceuticals
S2 Therapeutics
SACCO
Sagard Healthcare Royalty Partners
Sage Therapeutics
Salix Pharmaceuticals
Sam Amer
Sanara MedTech
Sandoz
Sanofi
Sanofi-Aventis
Sanofi-Pasteur
Sanpellegrino Cosmetics
Santarus
Santen Pharmaceutical
Sanuwave Health
SA Pathology
Sapientia Pharmaceuticals
Sarepta Therapeutics
Schrodinger
Scopus BioPharma
Seagen
Seattle Genetics
Seelos Therapeutics
Sekris Biomedical
Senetek
Senior Paradise
Sensory Cloud
Seqirus
Seres Therapeutics
Sermonix Pharmaceutical
Sesen Bio
SevenScore Pharmaceuticals
Shanghai Pharmaceuticals Holdings
Sheba Medical Center
Shenzhen BioScien Pharmaceuticals
Shield Therapeutics
Shionogi
Shire Pharmaceuticals
Shore Therapeutics
Siemens Healthcare Diagnostics
Sigma-Tau
Sinclair Pharmaceuticals
Sinobiopharma
Sinopharm
Sio Gene Therapies
Skinvera
Skyline Diagnostics
Solarvest BioEnergy
Soliance
Soligenix
Sonoma BioTherapeutics
Sorrento Therapeutics
Spectranetics
Spencer Pharmaceutical
Spinal USA
St. Jude Children's Research Hospital
STADA Arzneimittel
Staidson (Beijing) BioPharmaceuticals
Stanford University
Stealth BioTherapeutics
Stellar Biotechnologies
St Jude Medical
Stoke Therapeutics
Strongbridge Biopharma
Sucampo AG
SUDA Pharmaceuticals
Sumitomo Dainippon Pharma
Sunesis Pharmaceuticals
Sunovion Pharmaceuticals
Sun Pharmaceutical
SuperNova Diagnostics
Sutro Biopharma
Swedish Orphan Biovitrum
SymBio Pharmaceuticals
Symbollon
Syndax Pharmaceuticals
Synergy Strips
Syntopix
Tactical Relief
Taiba
TaiGen Biotechnology
Taiho
Takeda Pharmaceutical
Talaris Therapeutics
Tango Therapeutics
Target Group
Tauriga Sciences
TB Alliance
TearLab
Technion Research and Development Foundation
Teijin
Telomir Pharmaceuticals
Tesaro
Tetra Bio-Pharma
TetraLogic Pharmaceuticals
Teva Pharmaceutical Industries
Texas A&M University
Texas Heart Institute
TFF Pharmaceuticals
TG Therapeutics
Therakine
TherapeuticsMD
Theravance
Theravance Biopharma
The Regents of the University of California
Thorne Research
Threshold Pharmaceuticals
TiGenix
Tilray
Titterington Veterinary Services
Tiziana Life Sciences
Tocagen
TONIX Pharmaceuticals
Torii Pharmaceutical
TRACON Pharmaceuticals
Tramorgan
Transgene
Travere Therapeutics
Trellis Bioscience
Trevena
Trimedyne
Trimeris
TrovaGene
TTFactor
Tufts University
Turnstone Biologics
Tyme Technologies
Ultragenyx Pharmaceuticals
Uluru
Unigene Laboratories
UniQure
Universal Cells
University College Dublin
University Health Network
University of Alberta
University of California
University of Central Florida Research Foundation
University of Colorado
University of Florida Research Foundation
University of Geneva
University of Louisville
University of Missouri
University of Notre of Dame
University of Pennsylvania
University of Texas
University of Virginia
University of Western Sydney
University of Zurich
UOP
Uppsalagruppen Medical
Upstream Peripheral Technologies
UroGen Pharma
Valeant Pharmaceuticals
ValiPharma
Valneva
Valor Biotherapeutics
Vanderbilt University
Vasomune Therapeutics
Vaxent
VBL Therapeutics
Veloxis Pharmaceuticals
Veracyte
Verenium
Verity Pharmaceuticals
VeroScience
Vertex Pharmaceuticals
Vida Concepts
Vifor Pharma
ViiV Healthcare
Virbac
Viropharma
VistaGen Therapeutics
Vividion Therapeutics
Vivus
VolitionRX
Voronoi
Voyager Therapeutics
Vyera Pharmaceuticals
VYNE Therapeutics
Vyrix Pharmaceuticals
Watson Pharmaceuticals
WAVE Life Sciences
Wigen Biomedicine
Wisconsin Alumni Research Foundation
World Class Extractions
WPD Pharmaceuticals
WUGEN
Xbrane Bioscience
Xencor
Xlife Sciences
XPhyto Therapeutics
XTL Biopharmaceuticals
Xynomic Pharmaceuticals
Yale University
Yeda Research and Development Company
Yeugnam University
Yissum Research Development
ZAI Laboratory
Zalicus
Zenitech
Zenith Epigenetics
Ziopharm Oncology
Zogenix
ZS Pharma
Zymeworks
For more information about this report visit
https://www.researchandmarkets.com/r/pilfnx
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Vaccine
100 Deals associated with Bharat Biotech International Ltd.
Login to view more data
100 Translational Medicine associated with Bharat Biotech International Ltd.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 03 Jul 2024
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
1
3
Phase 1 Clinical
Phase 2 Clinical
1
3
Phase 3 Clinical
Approved
15
6
Other
Login to view more data
Current Projects
| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
Rotavirus vaccine 116E(Bharat Biotech International Ltd.) | Rotavirus Infections More | Approved |
iNCOVACC ( SARS-CoV-2 S protein ) | COVID-19 More | Approved |
Influenza A H1N1 vaccine(Bharat Biotech International Ltd.) | Influenza, Human More | Approved |
Typhoid vaccine Vi polysaccharide(Bharat Biotech International Ltd.) | Typhoid Fever More | Approved |
Typhoid Vi capsular polysaccharide tetanus toxoid protein conjugate vaccine(Bharat Biotech International Ltd.) | Typhoid Fever More | Approved |
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free